Epidemiology of Haemophilus
Before the introduction of Haemophilus infl uenzae type b (Hib) conjugate vaccines, rates of invasive H. infl uenzae disease among indigenous people of the North American Arctic were among the highest in the world. Routine vaccination reduced rates to low levels; however, serotype replacement with n...
| Other Authors: | |
|---|---|
| Format: | Text |
| Language: | English |
| Subjects: | |
| Online Access: | http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.306.7423 http://wwwnc.cdc.gov/eid/article/14/1/pdfs/07-0822.pdf |
| Summary: | Before the introduction of Haemophilus infl uenzae type b (Hib) conjugate vaccines, rates of invasive H. infl uenzae disease among indigenous people of the North American Arctic were among the highest in the world. Routine vaccination reduced rates to low levels; however, serotype replacement with non–type b strains may result in a reemergence of invasive disease in children. We reviewed population-based data on invasive H. infl uenzae in Alaska and northern Canada from 2000–2005; 138 cases were reported. Among 88 typeable isolates, 42 (48%) were H. infl uenzae type a (Hia); 35 (83%) occurred in indigenous peoples. Among Hia patients, median age was 1.1 years; 62 % were male; 1 adult died. Common clinical manifestations included meningitis, pneumonia, and septic arthritis. Overall annual incidence was 0.9 cases per 100,000 population. Incidence among indigenous children <2 years of age in Alaska and northern Canada was 21 and 102, respectively. Serotype a is now the most common H. infl uenzae serotype in the North American Arctic; the highest rates are among indigenous children. Haemophilus infl uenzae causes illnesses ranging from local respiratory infection to serious invasive disease, including meningitis, epiglottitis, septic arthritis, and septicemia (1). Among the encapsulated strains (a to f) that have been identified, H. infl uenzae serotype b (Hib) is the most virulent (1–4). Nonencapsulated (nontypeable) strains |
|---|